Asset Details
Do you wish to reserve the book?
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Do you wish to request the book?
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
2024
Overview
In this trial involving patients with IgA nephropathy, sibeprenlimab, a humanized IgG2 monoclonal antibody that blocks a proliferation-inducing ligand, resulted in a greater decrease in proteinuria than placebo.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Allergy
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Biopsy
/ Diabetes
/ Epidermal growth factor receptors
/ Glomerulonephritis, IGA - complications
/ Glomerulonephritis, IGA - drug therapy
/ Glomerulonephritis, IGA - genetics
/ Humans
/ Ligands
/ Placebos
/ Proteins
/ Tumor Necrosis Factor Ligand Superfamily Member 13 - antagonists & inhibitors
/ Tumor Necrosis Factor Ligand Superfamily Member 13 - genetics
/ Urine
We currently cannot retrieve any items related to this title. Kindly check back at a later time.